Research & Reports

Whitepapers, research reports and market data

#4583 ×

Research & Reports

Sep 20, 2026•1 min read

Daraxonrasib Demonstrates Tumor Reduction in NSCLC in Early Study

Within a week of U.S. approval for pancreatic cancer, daraxonrasib showed tumor shrinkage in over 30% of non‑small cell lung cancer patients in a small trial.